Findings for dual-acting are limited to in vitro studies that demonstrate guselkumab binds to CD64, which is expressed on the surface of IL-23 producing cells in an inflammatory monocyte model.

A phase 3 study found that a subcutaneous version of Johnson & Johnson's Tremfya (guselkumab) was effective in treating Crohn ...

Guselkumab achieved clear or almost clear skin in 74.2% of patients with moderate plaque psoriasis, compared to 12.4% on placebo. The VISIBLE study showed rapid and significant clearance of scalp ...

Johnson & Johnson recently announced that TREMFYA® (guselkumab) demonstrated rapid and significant clearance in moderate to severe scalp psoriasis (PsO) and significant improvement in scalp itch, as ...

A greater number of patients treated with subcutaneous guselkumab induction and maintenance vs placebo achieved clinical remission and endoscopic response at 48 weeks in the Phase 3 GRAVITI study1 ...

Treatment persistence varied by biologic therapy use, sex, and diagnostic codes among patients with psoriasis.

VIENNA — Guselkumab has been shown to be efficacious vs placebo in patients with moderately to severely active Crohn’s disease (CD), regardless of prior biologic therapy exposure, according to ...

At week 16, an IGA score of 0 or 1 was met for guselkumab vs placebo in scalp (75.0% vs 14.5%), face (87.8% vs 28.6%), intertriginous (86.5% vs 28.8%) and genital (78.0% vs 37.5%) psoriasis.

Guselkumab administered every 8 weeks (Q8W) leads to durable improvement in disease activity along with improvements in both skin and joint symptoms over 2 years in patients with psoriatic ...

You may report side effects to Health Canada at 1-866-234-2345. Before using guselkumab, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product ...

First-of-its-kind Phase 3b study shows TREMFYA ® achieved statistical significance across all primary and secondary endpoints in low body surface area psoriasis with special site involvement ...

About TREMFYA® (guselkumab) Developed by Johnson & Johnson, TREMFYA® is the first approved fully-human, dual-acting monoclonal antibody designed to neutralize inflammation at the ...